Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055676 | 0.86 | ALDH1A1 (0.66) | TDP1MAPTALDH1A1LMNAGAA | |
| SCHEMBL133029 | 0.81 | TDP1 (0.70) | TDP1MAPTALDH1A1LMNAGAA | |
| SCHEMBL136844 | 0.81 | TDP1 (0.74) | TDP1MAPTALDH1A1LMNAGAA | |
| SCHEMBL135846 | 0.80 | TDP1 (0.72) | TDP1MAPTALDH1A1LMNAGAA | |
| SCHEMBL15199361 | 0.79 | PTPRC (0.47) | MAPTALDH1A1GAAHPGDANO1 | |
| SCHEMBL3500340 | 0.77 | PTPRC (0.58) | MAPTALDH1A1LMNAGAAHPGD | |
| SCHEMBL3452996 | 0.77 | ALDH1A1 (0.60) | MAPTALDH1A1LMNAGAAHPGD | |
| SCHEMBL135808 | 0.77 | PTPN1 (0.46) | TDP1MAPTALDH1A1LMNAGAA | |
| SCHEMBL132839 | 0.75 | KMT2A (0.80) | TDP1MAPTALDH1A1LMNAGAA | |
| SCHEMBL3495630 | 0.75 | MAPT (0.67) | TDP1MAPTALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| EP-2640729-B1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-2640729-B1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-8809363-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-8809363-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| WO-2012066442-A1 | INHIBITORS OF HIV REPLICATION | PFIZER LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| EP-2430029-A1 | THIENO [2, 3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-03-08 | — | — | US | disclosed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLRMT, MAVS | TDP1 563/4885MAPT 2130/4885ALDH1A1 4304/4885 |
| US-20120136023-A1 | Inhibitors of HIV Replication | RTF2, POLRMT, MAVS | TDP1 563/4885MAPT 2130/4885ALDH1A1 4304/4885 |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | TDP1 928/4885MAPT 2061/4885ALDH1A1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.